Industry Standard Research’s (ISR) “2013 CRO Quality Benchmarking – Phase IV Service Providers” report provides pharmaceutical sponsors and clinical service providers an independent and comprehensive analysis of CRO service quality to assist with the outsourcing of Phase IV clinical trial activities. This year, ISR’s Phase IV report includes data from 208 unique service evaluations across 27 Phase IV service providers.

1. EW
PR
EV
I
2013 CRO Quality
Benchmarking – Phase IV
Service Providers
Info@ISRreports.com
©2013 Industry Standard Research
www.ISRreports.com

2. act with confidence
Report Overview
Industry Standard Research’s (ISR) “2013 CRO Quality Benchmarking – Phase IV Service Providers” report
provides pharmaceutical sponsors and clinical service providers an independent and comprehensive analysis
of CRO service quality to assist with the outsourcing of Phase IV clinical trial activities.
This year, ISR’s Phase IV report includes data from 208 unique service evaluations across 27 Phase IV
service providers.
Q4,
2013
Publication date
Report Structure:
1. Outsourcing Behaviors, Attitudes, Beliefs, and Intentions
•
•
•
•
Phase IV Leaders
Proposal Volume
Service Provider Usage
Service Provider Cost Perceptions
106
2. Sponsors’ Service Provider Selection Drivers
208
3. Service Provider Performance and Scorecards
Respondents
Service Encounters
221
Charts and Graphs
138
Pages
• Most Important Service Provider Attributes
• Service Provider Attributes Gaining Importance
• “Staff Characteristics” Ratings
• “Operational Excellence” Ratings
• “Organizational & Finance” Ratings
4. Satisfaction, Customer Loyalty, and the Expectations and
Performance Index (EPI™)
5. Company Service Quality Profiles
6. Study Data
What you will learn in this report:
•
•
•
Performance of 27 Phase IV CROs, 7 of which received in-depth profiles, measured across 26
critical dimensions of service quality
How sponsors make their clinical outsourcing decisions, including which service attributes drive selection
Study sponsors’ satisfaction, willingness to recommend, and likelihood of repeat use for the 27
included Phase IV CROs
How you can use this report:
For study sponsors, this report offers insight into CRO service quality and empowers you to make more
informed late phase outsourcing decisions by providing evaluation and selection tools that will lead to
better service experiences.
For clinical service providers, this report offers insight into your service quality and your competitors’
quality that will allow you to compete more effectively, deliver higher quality services, and better
understand the needs of your customers.
Learn how you can use this report.
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
2

3. act with confidence
Report Metrics
CROs Included in this Report
•
•
•
•
•
•
•
•
•
Accelovance
Aptiv Solutions
BioClinica
Charles River Laboratories
Chiltern
Cognizant
Covance
DaVita Clinical Research
DCRI – Duke
•
•
•
•
•
•
•
•
•
Eurofins
ICON
INC Research
inVentiv Health
Medpace
Novella
PAREXEL
PPD
PRA
•
•
•
•
•
•
•
•
•
Premier Research
Quintiles
Mapi
RPS
SGS
Tata
Theorem
UBC
Worldwide Clinical Trials
Service Quality Metrics
Staff Characteristics
Operational Excellence
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Commercial market knowledge
CRA quality
Minimizing staff turnover
Project manager quality
Project team chemistry
Therapeutic expertise
Timely project communications
Organization & Finance Characteristics
•
•
•
•
•
•
Breadth of services
Financial strength / stability
Global footprint
Low cost
Minimizing change orders
Overall value
Data quality metrics
Local market / regulatory knowledge
Meeting database lock timelines
Meeting first patient / first visit timelines
Meeting overall project timelines
Network of sites / investigators
Offers innovative solutions
Patient / volunteer recruitment strategy
Positive experience with service provider
Speed of site / investigator recruitment
Speed of site start-up
Technology for real-time access to data
Up-front contingency planning and trial risk
management
Respondent Demographics (N=106)
Participant Job Title
Participant Geography
6% C-level
4% President
9% Vice President
48% Director
28% Manager
5% Other
65%
North
America
Participant Company Size
59% Large Companies
(R&D $1B or more)
22%
Europe
13%
Asia/
Middle East/
India
27% Mid-Size
Companies (R&D
$100M-$999M)
13% Small Companies
(R&D less than $100M)
Participant Experience: Mean = 15.5 years
Up next: Full table of contents and sample pages
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
3

4. act with confidence
Table of Contents
Full table of contents and additional sample pages are available in the full preview. Download it on our website: http://www.isrreports.com/product/2013cro-quality-benchmarking-phase-iv-service-providers/
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
4

5. act with confidence
Report Introduction
Introduction
act with confidence
Introduction
Welcome to the 2013 edition of the clinical trial and pharmaceutical environment is
One way to think about the Russian CRO Quality Benchmarking report for Phase
IV serviceof the country as a publically traded pharmaceutical pride in itsIf you of CRO
to think providers. Industry Standard Research (ISR) takes company� suite were
leafing through a prospectus or an this report, dedicated to would find a comQuality Benchmarking Reports andinvestor presentation, you the Phase IV industry, is
pany with strong macro fundamentals, information and has two very simple missions:
no different. This report has a wealth ofhistoric growth, inconsistent performance,
and some regulatory uncertainty� In short, Russia has many of the same characteristics as a mid-stage pharmaceutical company� And, if you take a portfolio theory
approach to investing, you would likely want to invest some portion of your assets
1.in Russia� Why? companies make more informed CRO selection decisions
Help sponsor
Yes, in one sense service quality depends almost solely on the people who
th
↑ Macroeconomics: sponsor’s world’s manager, economy
deliver the study - theRussia is theproject 10 largest the CRO’s project manager,
engaged clinical recognition: Joined the World Trade Organization (WTO) in 2012
↑ International investigators, diligent CRAs, etc. And if you get a different
study team each time you buy that company’s services, shouldn’t you expect
↑ Positive balance sheet: Russia has ~$240B trade surplus from fossil fuel reserves
service quality to fluctuate? And if industry turnover is high and CROs simply
↑ important staff back and forth, shouldn’t we expect any differences in
pass Focus: Putin announced $3�9B plan aimed at having 90% of medicines to be
locally produced by 2020
delivery quality between and among service providers to simply wash out over
time? But that’s notstructure: Medicines Insurance System providers. is to be in
↑ Reimbursement what happens. At least not for all (Aug 2012) CRO personnel
place by 2020 that infrastructure, processes, training, SOPs, learning and
are supported by sites,will include a tiered rate of reimbursement, depending on
the nature of the illness, and dynamics, and endless other
development budgets, cultural improve access to medications factors that lead to
some organizations pharmaceutical market has been growing 17% annually since
↑ Growth: Russian being meaningfully more effective than others. And some
organizations that simply rise and fall with the tide.
2005
ISR’s Untapped potential: Manyare designed to be smart enough to capture these
↑ Benchmarking studies patients are treatment naïve, offering opportunities
nuances and help to create a more educated buying audience.
for clinical trial patient recruitment
↓ Uncertainty: Regulatory environment and customs practices are unstable and
2. Help service providers optimize Operational and Marketing strategies
unpredictable
↓ Difficult: In 2012 what it does not know is broken. While it of economies
A company can’t fix the World Bank ranked Russia 122nd on their listis almost certainly
by ease of doing business, 21 spots below China
true that you (or your sales teams) speak with your customers and have a sense
of the levels of satisfaction / dissatisfaction with your services, it is just as certain
↓ Skills: Finding highly qualified healthcare professionals can be difficult
that you’re seeing half of the picture. Not every customer tells you the whole
↓ Protection: IP protection is concerning
story. Some will make clear to you any and all delivery shortcomings. Some
will stop short of full disclosure for various reasons. Some will leave dissatisfied
without saying a word. And some will leave dissatisfied and say a lot of words...
sometimes to their colleagues.
It’s also important to know what your company is up against from a competitive
standpoint. Yes, your company’s ratings may represent opportunities to improve
delivery and loyalty, but they might also represent opportunities to tout your
leadership and strength on traits that sponsors highly value.
www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile
7
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
5

6. act with confidence
Sample Page
Most
Important
Service
Provider
Attributes
“Please
review
the
following
attributes
and
select
the
5
most
important
to
you
when
selecting
a
provider
for
Phase
IV
services.”
(Base
=
106)
“Among
the
following
attributes,
please
select
the
1
most
important
to
you
when
selecting
a
provider
for
Phase
IV
services.”
(Base
=
106)
1%
Breadth
of
services
13%
5%
Change
order
minimizanon
metrics
10%
3%
Commercial
market
knowledge
20%
5%
CRA
quality
13%
4%
Data
quality
metrics
Detailed
plan
for
nmely
project
communicanons
5%
Financial
strength/
stability
18%
5%
5%
10%
2%
Global
footprint
24%
5%
Local
market
/
Regulatory
knowledge
38%
9%
Low
cost
Metrics
for
database
lock
nmelines
Metrics
for
first
panent
/
first
visit
nmelines
5%
4%
Metrics
for
meenng
overall
project
nmelines
4%
53%
5%
4%
1%
Metrics
for
site
/
Invesngator
recruitment
16%
Most
Important
5%
Top
5
5%
3%
Metrics
for
site
start-­‐up
3%
Network
of
sites/
invesngators
25%
3%
Offers
innovanve
solunons
15%
36%
Overall
value
3%
Panent/
volunteer
recruitment
strategy
22%
12%
Prior
posinve
experience
with
service
provider
Project
manager
quality
6%
Project
team
chemistry
29%
Data has been alphabetized. Data
available 25%
report.
in full
5%
5%
1%
Staff
turnover
metrics
6%
Technology
for
real-­‐nme
access
to
data
5%
Therapeunc
expernse
5%
4%
Up-­‐front
connngency
planning,
risk
management
0%
69%
9%
40%
17%
25%
50%
75%
43
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
6

7. act with confidence
Sample Company Profile
Full table of contents and additional sample pages are available in the full preview. Download it on our website: http://www.isrreports.com/product/2013cro-quality-benchmarking-phase-iv-service-providers/
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
7

8. act with confidence
Ordering Information
For pricing and ordering information, please visit our website: http://www.
isrreports.com/product/2013-cro-quality-benchmarking-phase-iv-serviceproviders/
www.ISRreports.com ©2013 | Preview of: 2013 CRO Quality Benchmarking – Phase IV Service Providers
8

9. The ISR Difference
act with confidence
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
vs.
The Common
Syndicated Report
How confident are you?
Research methods
Mostly primary
research;
always appropriate
for the topic
vs.
vs.
One size fits all;
usually publically
available data
Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
vs.
Struggle to recruit the right
targets and enough of them
Respondents
Sophisticated screening
ensures genuine
decision-makers
vs.
Undisclosed
methodologies and
respondent demographics
Sample Sizes
Robust sample sizes that
instill confidence
vs.
Often insufficient industry
representation that leaves you
defending results
Analysts
Decades of experience
means more insights that are
immediately usable
vs.
vs.
Junior analysts capable of
reporting numbers
www.ISRreports.com ©2013 | ©2013 | Preview of: Benchmarking the Pharma Industry’sService Functions
www.ISRreports.com Preview of: 2013 CRO Quality Benchmarking – Phase IV HEOR Providers
9